Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59 (R) Adjuvant

Trial Profile

A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59 (R) Adjuvant

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza A virus H7N9 vaccine Seqirus (Primary) ; MF 59
  • Indications Influenza A virus H7N9 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 21 Nov 2019 Planned End Date changed from 30 Nov 2019 to 22 Apr 2020.
    • 21 Nov 2019 Planned primary completion date changed from 30 Nov 2019 to 22 Apr 2020.
    • 21 Nov 2019 Status changed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top